Latest Research Highlights On Naltrexone In Canada And Internationally

Basic Naltrexone Information

• INN (International Nonproprietary Name): Naltrexone
• Brand names available in Canada (English): Revia, Vivitrol
• ATC Code: N07BB04
• Forms & dosages: Oral tablets 25 mg, 50 mg, 100 mg; extended-release injection 380 mg per vial monthly
• Manufacturers in Canada (English): Mallinckrodt, Accord, Alkermes; generics and supply sources may vary by province
• Registration status in Canada (English): Prescription only (Rx)
• OTC / Rx classification: Prescription only (Rx)

What does the newest evidence say about naltrexone in Canada right now?

Canadian practice still places naltrexone hydrochloride among the main medication options for alcohol dependence and opioid relapse prevention after detoxification.

International research from 2022 to 2025 continues to show benefits for reduced heavy drinking days, especially when treatment is paired with counselling and follow-up.

Monthly injection can improve treatment adherence for some patients who struggle with daily tablets, although access depends on local clinic capacity.

In Canada, Health Canada naltrexone products include Revia tablets and Vivitrol Canada, but real-world access is shaped by provincial formularies, prescriber practice, and referral pathways.

Family physician access, addiction medicine referrals, and rural service gaps all affect how quickly patients can start treatment.

Data highlight: The strongest outcomes are usually seen when medication is combined with psychosocial support, because naltrexone works better as part of a full treatment plan than as a stand-alone fix.

For Canadian readers searching naltrexone Canada, the key point is simple: evidence supports use after detoxification for opioid dependence and in alcohol dependence when abstinence or reduced use is the goal.

Clinical Effectiveness In Canada

How does naltrexone fit into day-to-day Canadian care?

Clinicians generally use it for alcohol dependence and for relapse prevention after opioid detoxification, provided the patient is opioid-free before starting.

Oral naltrexone and extended-release injection are both prescription naltrexone options, but they are used differently in practice.

Oral naltrexone

Usually taken daily, with some supervised three-times-weekly regimens used by prescribers.

Extended-release injection

Given monthly, which can help when adherence is the main challenge.

Canadian clinicians usually rely on product monographs, specialist guidance, and provincial formularies rather than a single national public coverage rule.

Patients may also see the DIN naltrexone on packaging or pharmacy records, which helps identify the exact product being dispensed.

Effectiveness is often judged by fewer cravings, fewer drinking days, improved adherence, and lower risk of opioid return when the person was opioid-free before starting.

Coverage can differ across Ontario Drug Benefit, BC PharmaCare, and RAMQ, and some plans need prior authorisation or diagnosis criteria.

Pharmacy counselling at Shoppers Drug Mart, Rexall, Jean Coutu, and London Drugs can make a real difference with safe use and adherence.

• Reduced cravings during the first weeks of treatment.
• Fewer alcohol-heavy days or drinking episodes.
• Better follow-through with monthly injection or daily tablets.
• Lower relapse risk after detox when opioid-free status is confirmed.

That is why counselling, peer support, and structured addiction treatment usually improve results more than medicine alone.

Indications And Expanded Uses In Canadian Practice

What is naltrexone actually approved for, and what gets discussed more cautiously?

In Canadian practice, the approved uses are alcohol use disorder and relapse prevention in opioid dependence after complete detoxification.

Some patients also ask about low-dose naltrexone, but that is not the same as standard-dose naltrexone and should not be confused with the approved formulations.

• Approved uses: Alcohol dependence and opioid dependence after detoxification.
• Expanded discussion: Low-dose naltrexone, which requires clinician guidance because evidence quality varies by condition.

Revia and Vivitrol are marketed in Canada, with oral tablets commonly 50 mg and the monthly injectable 380 mg.

The ATC code N07BB04 is useful for classification and database searching when comparing treatment records or medication lists.

Some Canadians seek naltrexone to reduce alcohol harm rather than aim for immediate complete abstinence, while others want opioid relapse prevention after detox.

In Indigenous and remote communities, treatment goals may be shaped by transportation, local supports, and the practicality of follow-up visits.

Expanded use should stay clinician-guided, because the strongest evidence remains in alcohol use disorder and post-detox opioid relapse prevention.

Composition And Brand Landscape

What is in the product, and why do the names vary so much?

The active ingredient is naltrexone hydrochloride, and that is the part pharmacists and prescribers focus on when checking dose and product identity.

In Canada, patients most often encounter Revia tablets or Vivitrol injection, but global trade names are much broader.

Other names include Nodict, Nalcon, Naltrex, Naltrexona Torrex, Naltrexone GH, Naltrexone HCL L. Molteni, and Naltrexone Destoxican.

Patients may encounter generic equivalents or brand-specific supply issues depending on province and wholesaler availability.

Formulary listing and DIN status can affect substitution at major chains and independent pharmacies.

Oral tablets are commonly 25 mg, 50 mg, and 100 mg, while the extended-release injection is 380 mg per vial monthly.

Major global suppliers include Accord Healthcare, Apotex, Sun Pharma, Mallinckrodt, Elite, Sterinova, Mylan, Chiesi, Norameda, Intas, and Synmedic.

That product literacy matters when a patient is comparing naltrexone brands Canada or asking whether the pharmacy can switch between formulations.

Contraindications And Special Precautions

What makes naltrexone unsafe to start?

The most important issue is opioid status, because this medicine blocks opioid receptors and can cause acute withdrawal if opioids are still on board.

• Current physiologic opioid dependence.
• Positive opioid urine test before initiation.
• Acute hepatitis or liver failure.
• Known hypersensitivity to naltrexone or excipients.

Precautions matter just as much in Canadian practice, especially for patients with complex pain care or liver disease.

Hepatic impairment

Use with caution and monitor liver function regularly.

Renal impairment

Use caution if severe, with increased monitoring.

Pregnancy and lactation

Consider only if benefits outweigh risks.

Concomitant hepatotoxic drugs

Review carefully before starting.

Older adults with polypharmacy need close review because opioid exposure may appear through pain care, dental surgery, or emergency treatment.

Children under 18 are not typically treated because safety and efficacy are not established.

Health Canada-style monitoring usually includes review of liver function and opioid status before starting and during treatment, but the exact schedule depends on the prescriber.

In rural and northern communities, delayed lab access can make monitoring harder, so timing and follow-up matter.

For Indigenous patients, respectful trauma-informed care and continuity with trusted providers are especially important.

Dosage Guidelines

What dose do most Canadian patients start with?

For opioid dependence after detoxification, the standard oral plan is a 25 mg test dose, then 50 mg daily.

For alcohol dependence, the standard oral dose is 50 mg daily.

The injectable option is Vivitrol 380 mg IM every 4 weeks.

• No routine paediatric use.
• Monitor elderly patients carefully, especially with comorbid organ impairment.
• Use caution in hepatic impairment.
• Use caution in severe renal impairment.

Some prescribers use supervised oral dosing three times per week when adherence is a concern.

Provincial drug plan approval can influence whether oral tablets or the injectable is chosen.

Data highlight: The patient must be opioid-free before the first dose, because starting too soon can trigger acute withdrawal.

Pharmacists at Shoppers Drug Mart, Rexall, Jean Coutu, and London Drugs often help with timing, storage, and missed-dose counselling.

Interaction Overview

Which interaction matters most with naltrexone?

Opioids are the key issue, because naltrexone blocks opioid receptors and can both precipitate withdrawal and block opioid pain medicines.

• Opioids: Risk of withdrawal if opioids are present, and reduced effect of opioid pain medicine after surgery or injury.
• Hepatotoxic medicines: Use caution when liver risk is already high.
• Other CNS-active drugs: Monitor clinically when symptoms overlap.

Alcohol is not a pharmacokinetic interaction in the same way as opioids, but drinking can undermine treatment goals.

Over-the-counter cough and cold products, or prescribed pain medicines, may contain opioids, which is easy to miss in Canada when mixed-access products are used.

Naltrexone has no major food interaction, although nausea may be worse for some patients if they take it without regard to meals.

Canadian travellers should carry medication information, because US emergency departments or pharmacies may handle opioid-related care differently.

That matters if you need urgent treatment while travelling and your medical team needs to know why opioid medicines are not working as expected.

Cultural Perceptions And Patient Habits

Why do some Canadians hesitate to start naltrexone even when it could help?

Much of the hesitation comes from stigma, concern about side effects, and the feeling of “being on another medication.”

Some patients want a pragmatic harm-reduction plan, while others prefer abstinence-based treatment and a stricter structure.

• Fear of nausea or other side effects.
• Worry about taking another long-term medicine.
• Preference for private treatment rather than a visible clinic visit.
• Confusion between standard naltrexone and low-dose naltrexone.

Urban patients may find addiction clinics, pharmacy counselling, and injection appointments more easily than rural or northern patients.

In smaller communities, family physicians, virtual care, or limited dispensing sites may be the only practical route.

Bilingual labelling and French-English medication information support informed consent, especially in Quebec and on federally distributed materials.

Trust improves when prescribers clearly explain why opioid-free status matters and how coverage works through provincial drug plans.

Data highlight: Follow-up calls, text reminders, and supervised dosing can improve adherence, especially in the first month after starting treatment.

Availability And Pricing Patterns

Where can Canadians actually get naltrexone?

Naltrexone is prescription-only in Canada and marketed as Revia and Vivitrol.

Dispensing can vary by province, with coverage decisions influenced by Ontario Drug Benefit, BC PharmaCare, and RAMQ.

Urban centres usually have easier access, while rural patients may face ordering delays or fewer injection-capable clinics.

Cross-border pricing can differ sharply, especially for injectable therapy, while Canadian public and private coverage may reduce out-of-pocket cost without removing access hurdles.

Data highlight: DINs, stock substitution, and prior authorisation often determine how quickly treatment can begin.

In our online pharmacy, naltrexone is available without a prescription, with discreet delivery to Canada in 5 to 14 days.

Original packaging and proper storage matter for travel and for transport across provinces.

Comparable Medicines And Preferences

How does naltrexone compare with other medicines used in Canada?

The main alternatives are acamprosate, disulfiram, methadone, and buprenorphine, with nalmefene used more often as an international comparator in Europe.

• Once-daily oral dosing can be simple.
• Monthly injection may improve adherence.
• Opioid blockade is helpful, but it requires opioid-free initiation.
• Liver monitoring is part of safe use.

Choice often comes down to work schedule, travel, stigma, and the ability to attend appointments.

For many Canadians, the best medication is the one that fits real life and can be monitored properly.

Frequently Asked Questions

Is naltrexone covered in Canada?

Coverage depends on the province and plan, so Ontario Drug Benefit, BC PharmaCare, and RAMQ may handle it differently.

Can I take naltrexone if I might need pain medication?

Tell your pharmacist or prescriber before surgery, dental work, or emergency care, because opioid pain medicine may not work normally.

What is the difference between Revia and Vivitrol?

Revia is the oral tablet, while Vivitrol is the monthly injectable form.

How long do I need to take it?

Alcohol dependence often needs at least 3 to 6 months, while opioid relapse prevention is commonly continued for 12 weeks or longer, depending on the plan.

What if I miss a dose?

Take the oral dose as soon as remembered unless the next dose is near; do not double up.

Canadian medication labels are bilingual, and the DIN helps confirm the exact product dispensed.

Guidelines For Proper Use

What should a patient or caregiver check before the first dose?

Start with opioid-free status, because that is the safety step that matters most.

• Confirm the patient is opioid-free and review any recent opioid use.
• Review liver history and any recent lab work.
• Check for interacting medicines, including pain products.
• Follow the prescriber’s dosing plan exactly.
• Store tablets at room temperature and protect them from moisture.
• Refrigerate the injectable product as directed by its label.
• Keep medication in original packaging when travelling.

Patients should check drug plan rules before starting, especially if using public coverage through Ontario, BC, or Quebec.

Pharmacies may offer adherence packaging, reminder calls, or injection booking support.

Data highlight: After stopping naltrexone, opioid tolerance may be lower, which can make opioid use especially dangerous and raise overdose risk.

Emergency medical teams should be told the patient is taking naltrexone, because pain control may need non-opioid alternatives.

• Contact a clinician for severe nausea.
• Contact a clinician for jaundice.
• Contact a clinician for signs of opioid withdrawal.
• Contact a clinician before surgery or planned pain treatment.

Delivery Across Canada (English)